US › Healthcare

Bright Minds Biosciences Inc (DRUG)

US · Healthcare · Biotechnology

$77.35+4.84%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-10.6M
Profit YoY
-260.4%
EPS
$-1.09
EPS estimate
$-1.26

EPS came in at -1.09 against a street estimate of -1.26 — a beat of 13.5%.

Key statistics

Market cap
$718.8M
Forward P/E
0.0
P/B
3.26
Book value
$22.40
EPS (TTM)
$-2.44
52-week high
$123.75
52-week low
$33.96
50-day MA
$71.93
200-day MA
$75.71
Beta
0.10

Analyst view

Analysts rate Bright Minds Biosciences Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $167.36.

Shareholding

Insiders
12.00%
Institutions
93.02%

Largest institutional holders

FundStake
HHG PLC13.09%
Cormorant Asset Management, LLC10.80%
BlackRock Inc6.34%
Vivo Capital, LLC5.68%
BRAIDWELL LP5.50%
Adage Capital Partners Gp LLC5.05%
Vestal Point Capital LP5.02%
Driehaus Capital Management LLC4.41%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Bright Minds Biosciences Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.